Profound Medical (PROF) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$19.1M

Revenue (quarter)

$2.5M

Revenue growth (year over year)

+12.30%

Gross profit (trailing twelve months)

$13.7M

Gross margin

71.79%

Net income (trailing twelve months)

−$32.7M

Net income (quarter)

−$9.5M

Net income growth (year over year)

+39.22%

Net margin

−171.56%

Return on equity

−73.53%

EPS (trailing twelve months)

−$0.99

Book value per share

$1.36

P/E (trailing twelve months)

—

Price to book

4.96

Debt to assets

20.16%

Payout ratio

—

Dividend yield

—

Company profile

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

• Is Profound Medical (PROF) profitable?

  No. Profound Medical reported a net loss of $32.7M over the trailing twelve months.

• How much revenue does Profound Medical (PROF) make?

  Profound Medical generated $19.1M in revenue over the trailing twelve months, up 12.30% year over year.

• How do I buy stock in Profound Medical (PROF)?

  PROF trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.